Poly(ADP-ribose) polymerase

A new therapeutic target?

Domokos Gero, Csaba Szabo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose of review To overview the emerging data in the literature showing the role of poly(ADP-ribose) polymerase (PARP) in the pathogenesis of critical illness. Recent findings PARP, an abundant nuclear enzyme involved in DNA repair and transcriptional regulation, is now recognized as a key regulator of cell survival and cell death in response to noxious stimuli in various forms of cardiovascular collapse. PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues. The activation of PARP may also induce various cell death processes, and promotes an inflammatory response. In circulatory shock PARP plays a crucial role both in the development of early cardiovascular dysfunction and in the delayed systemic inflammatory response syndrome with associated multiple organ failure. Inhibition of PARP activity is protective in various models of circulatory shock. Summary A solid body of literature supports the view that PARP is an important target for therapeutic intervention in critical illness.

Original languageEnglish (US)
Pages (from-to)111-121
Number of pages11
JournalCurrent Opinion in Anaesthesiology
Volume21
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Critical Illness
Therapeutics
Shock
Cell Death
Systemic Inflammatory Response Syndrome
Multiple Organ Failure
DNA Repair
DNA Damage
Cell Survival
Enzymes

Keywords

  • Cardiovascular
  • Dysfunction
  • Inflammation
  • Peroxynitrite
  • Shock

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Poly(ADP-ribose) polymerase : A new therapeutic target? / Gero, Domokos; Szabo, Csaba.

In: Current Opinion in Anaesthesiology, Vol. 21, No. 2, 04.2008, p. 111-121.

Research output: Contribution to journalArticle

@article{2986395fcafd405395c6d87b863c96fe,
title = "Poly(ADP-ribose) polymerase: A new therapeutic target?",
abstract = "Purpose of review To overview the emerging data in the literature showing the role of poly(ADP-ribose) polymerase (PARP) in the pathogenesis of critical illness. Recent findings PARP, an abundant nuclear enzyme involved in DNA repair and transcriptional regulation, is now recognized as a key regulator of cell survival and cell death in response to noxious stimuli in various forms of cardiovascular collapse. PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues. The activation of PARP may also induce various cell death processes, and promotes an inflammatory response. In circulatory shock PARP plays a crucial role both in the development of early cardiovascular dysfunction and in the delayed systemic inflammatory response syndrome with associated multiple organ failure. Inhibition of PARP activity is protective in various models of circulatory shock. Summary A solid body of literature supports the view that PARP is an important target for therapeutic intervention in critical illness.",
keywords = "Cardiovascular, Dysfunction, Inflammation, Peroxynitrite, Shock",
author = "Domokos Gero and Csaba Szabo",
year = "2008",
month = "4",
doi = "10.1097/ACO.0b013e3282f63c15",
language = "English (US)",
volume = "21",
pages = "111--121",
journal = "Current Opinion in Anaesthesiology",
issn = "0952-7907",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Poly(ADP-ribose) polymerase

T2 - A new therapeutic target?

AU - Gero, Domokos

AU - Szabo, Csaba

PY - 2008/4

Y1 - 2008/4

N2 - Purpose of review To overview the emerging data in the literature showing the role of poly(ADP-ribose) polymerase (PARP) in the pathogenesis of critical illness. Recent findings PARP, an abundant nuclear enzyme involved in DNA repair and transcriptional regulation, is now recognized as a key regulator of cell survival and cell death in response to noxious stimuli in various forms of cardiovascular collapse. PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues. The activation of PARP may also induce various cell death processes, and promotes an inflammatory response. In circulatory shock PARP plays a crucial role both in the development of early cardiovascular dysfunction and in the delayed systemic inflammatory response syndrome with associated multiple organ failure. Inhibition of PARP activity is protective in various models of circulatory shock. Summary A solid body of literature supports the view that PARP is an important target for therapeutic intervention in critical illness.

AB - Purpose of review To overview the emerging data in the literature showing the role of poly(ADP-ribose) polymerase (PARP) in the pathogenesis of critical illness. Recent findings PARP, an abundant nuclear enzyme involved in DNA repair and transcriptional regulation, is now recognized as a key regulator of cell survival and cell death in response to noxious stimuli in various forms of cardiovascular collapse. PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues. The activation of PARP may also induce various cell death processes, and promotes an inflammatory response. In circulatory shock PARP plays a crucial role both in the development of early cardiovascular dysfunction and in the delayed systemic inflammatory response syndrome with associated multiple organ failure. Inhibition of PARP activity is protective in various models of circulatory shock. Summary A solid body of literature supports the view that PARP is an important target for therapeutic intervention in critical illness.

KW - Cardiovascular

KW - Dysfunction

KW - Inflammation

KW - Peroxynitrite

KW - Shock

UR - http://www.scopus.com/inward/record.url?scp=43249086853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249086853&partnerID=8YFLogxK

U2 - 10.1097/ACO.0b013e3282f63c15

DO - 10.1097/ACO.0b013e3282f63c15

M3 - Article

VL - 21

SP - 111

EP - 121

JO - Current Opinion in Anaesthesiology

JF - Current Opinion in Anaesthesiology

SN - 0952-7907

IS - 2

ER -